STAMPEDE investigators, Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', Lancet Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1 Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy : final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', The Lancet. Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1
Attard, Gerhardt; Murphy, Laura; Clarke, Noel W; Cross, William; Jones, Robert J; Parker, Christopher C; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Amos, Claire L; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Chowdhury, Simon; Malik, Zafar; Russell, J Martin; Gilson, Clare; Rush, Hannah; Bowen, Jo; Lydon, Anna; ... (2022). Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The lancet, 399(10323), pp. 447-460. Elsevier 10.1016/S0140-6736(21)02437-5 Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators 2022, ' Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol ', Lancet (London, England), vol. 399, no. 10323, pp. 447-460 . https://doi.org/10.1016/S0140-6736(21)02437-5